Xbira 250 mg Tablet contains abiraterone acetate, an androgen biosynthesis inhibitor used in combination with prednisone to treat metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC). It works by reducing androgen production, which can fuel prostate cancer growth. MedlinePlus

Key Benefits & Uses

• Effective treatment for mCRPC and high-risk CSPC.

• Reduces androgen levels to inhibit tumor growth.

• Improves overall survival rates in advanced prostate cancer.

• Offers an alternative for patients who have not responded to chemotherapy. Drugs.com

How to Use

• Take one 250 mg tablet orally once daily with water.

• Administer on an empty stomach, at least one hour before or two hours after a meal.

• Swallow the tablet whole; do not crush or chew.

• Always take in combination with prednisone as prescribed. FDA Access Data

Important Safety Information

• Contraindicated in women who are or may become pregnant due to potential fetal harm. FDA Access Data

• Use gloves when handling broken or crushed tablets.

• Monitor liver function regularly; dosage adjustments may be necessary for hepatic impairment. FDA Access Data

• Avoid co-administration with strong CYP3A4 inhibitors or inducers.

Common Side Effects

• Hot flashes

• Fatigue

• Joint swelling or pain

• Diarrhea

• Headache

• Muscle discomfort WebMD

Why Choose Xbira 250 mg Tablet

Xbira offers a targeted approach to prostate cancer treatment, effectively reducing androgen levels to slow tumor progression. Its combination with prednisone enhances efficacy and minimizes side effects, providing a comprehensive treatment option for advanced prostate cancer.